

Department of State Health Services Immunization Schedule

Age 🕨 12 months 1 month 2 months 15 18 24 4-6 11-12 13–18 4 6 **Birth** months months months months months Vaccine **v** years years years HepB #1 HepB #3 **HepB Series** Hepatitis B¹ HepB #2 Diphtheria, Td DTaP DTaP **DTaP** DTaP DTaP Td Tetanus, Pertussis² Haemophilus Hib Hib Hib Hib *influenzae* type b³ **Inactivated Poliovirus IPV** IPV **IPV IPV** Measles, Mumps, **MMR #1 MMR #2 MMR #2 Rubella**^₄ Varicella Varicella **Varicella**^₅ PCV **Pneumococcal⁶ PCV PCV PCV PCV** PPV **Influenza (Yearly) Influenza (Yearly)** Influenza⁷ Vaccines below red line are for selected populations **Hepatitis A⁸ Hepatitis A Series**

January 1, 2006

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines for children through age 18 years. Any dose not given at the recommended age should be given at any subsequent visit when indicated and feasible. Indicates age groups that warrant special effort to administer those vaccines not previously given.

Department of State Health Services Immunization Schedule

1. Hepatitis B (HepB) vaccine. All infants should receive the first dose of HepB vaccine soon after birth and before hospital discharge; the first dose may also be administered by age 2 months if the mother is hepatitis B surface antigen (HBsAg) negative. Only monovalent HepB can be used for the birth dose. Monovalent or combination vaccine containing HepB may be used to complete the series. Four doses of vaccine may be administered when a birth dose is given. The second dose should be given at least 4 weeks after the first dose, except for combination vaccines which cannot be administered before age 6 weeks. The third dose should be given at least 16 weeks after the first dose and at least 8 weeks after the second dose. The last dose in the vaccination series (third or fourth dose) should not be administered before age 24 weeks.

Infants born to HBsAg-positive mothers should receive HepB and 0.5 mL of hepatitis B immune globulin (HBIG) at separate sites within 12 hours of birth at separate sites. The second dose is recommended at age 1 to 2 months. The last dose in the immunization series should not be administered before age 24 weeks. These infants should be tested for HBsAg and antibody to HBsAg (anti-HBs) at age 9 to 15 months.

Infants born to mothers whose HBsAg status is unknown should receive the first dose of the HepB series within 12 hours of birth. Maternal blood should be drawn as soon as possible to determine the mother's HBsAg status; if the HBsAg test is positive, the infant should receive HBIG as soon as possible (no later than age 1 week). The second dose is recommended at age 1 to 2 months. The last dose in the immunization series should not be administered before age 24 weeks.

- 2. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose and the child is unlikely to return at age 15 to 18 months. The final dose in the series should be given at age ≥4 years. Tetanus and diphtheria toxoids (Td) is recommended at age 11 to 12 years if at least 5 years have elapsed since the last dose of tetanus and diphtheria toxoid-containing vaccine. Subsequent routine Td boosters are recommended every 10 years.
- 3. Haemophilus influenzae type b (Hib) conjugate vaccine. Three Hib conjugate vaccines are licensed for infant use. If PRP-OMP (PedvaxHIB® or ComVax® [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required. DTaP/Hib combination products should not be used for primary immunization in infants at ages 2, 4, or 6 months but can be used as boosters after any Hib vaccine. The final dose in the series should be administered at age ≥12 months.

- **4. Measles, mumps, and rubella vaccine (MMR).** The second dose of MMR is recommended routinely at age 4 to 6 years but may be administered during any visit, provided at least 4 weeks have elapsed since the first dose and both doses are administered beginning at or after age 12 months. Those who have not previously received the second dose should complete the schedule by age 11-12 years.
- 5. Varicella vaccine. Varicella vaccine is recommended at any visit at or after age 12 months for susceptible children (i.e., those who lack a reliable history of chickenpox). Susceptible persons aged ≥13 years should receive 2 doses given at least 4 weeks apart.
- 6. Pneumococcal vaccine. The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for all children aged 2 to 23 months. It is also recommended certain children aged 24 to 59 months. The final dose in the series should be given at age ≥12 months. Pneumococcal polysaccharide vaccine (PPV) is recommended in addition to PCV for certain high-risk groups including children with sickle disease, asplenia, HIV infection, or other immunocompromising conditions or chronic diseases. (Not required for school entry)
- 7. Influenza vaccine. Influenza vaccine is recommended annually for children aged ≥ 6 months with certain risk factors (including but not limited to, asthma, cardiac disease, sickle cell disease, human immunodeficiency virus infection, and diabetes), healthcare workers, and other persons (including household members) in close contact with persons at high risk (see MMWR 2004;53[RR-6]:1-40). In addition, healthy children aged 6 to 23 months and close contacts of healthy children aged 0-23 months are recommended to receive influenza vaccine because children in this age group are at substantially increased risk for influenza-related hospitalizations. For healthy persons aged 5-49 years, the intranasally administered, live, attenuated influenza vaccine (LAIV) is an acceptable alternative to the intramuscular trivalent inactivated influenza vaccine (TIV). See MMWR 2004;53(RR-6):1-40). Children receiving TIV should be administered a dosage appropriate for their age (0.25 mL if aged 6-35 months or 0.5 mL if aged \geq 3 years). Children aged ≤8 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by at least 4 weeks for TIV and at least 6 weeks for LAIV). (Not required for school/child-care entry)
- 8. Hepatitis A vaccine. Hepatitis A vaccine is recommended for children and adolescents in Texas. Children and adolescents who have not been immunized against hepatitis A can begin the hepatitis A immunization series during any visit. The 2 doses in the series should be administered at least 6 months apart.

Informed by recommendations of the 2005 Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP), and adopted by the Executive Commissioner of the Health and Human Services Commission on behalf of the Department of State Health Services, 1100 West 49th Street, Austin, Texas 78756. (800) 252-9152. The above information is available at www.ImmunizeTexas.com.